Resources

Glucose-lowering medication can influence COVID-19 pathogenesis and could have implications for treating patients with diabetes and COVID-19.

Are the mortality and cardiovascular benefits of SGLT-2 inhibitors limited to patients with type 2 diabetes who have established cardiovascular disease and renal disease?

Blood sugar levels of 70 to 160 mg/dL are considered normal, and anything outside these levels could negatively affect patients.

Are socioeconomic factors and obesity independently related to diabetes prevalence?

Long-term diabetes may lead to signs of cognitive decline in Latino patients as early as middle age.

Dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1RAs create an additive effect for increased anti-inflammation and vascular protection.

Measuring waist circumference could provide an inexpensive way to assess risk of developing insulin resistance.

GLP-1 receptor agonists are a pharmacologic treatment of type 2 diabetes with potential cardiorenal benefits.

Worse clinical outcomes are seen during the pandemic for non-Hispanic Black youth with T2D.

A1c goals are not a one-size-fits-all; here are some factors you might want to think about to help patients meet their target A1c goals.